In breast cancer, nuclear ERα levels are routinely assessed by immunohistochemical methods particularly to determine the dependency of a tumour on estrogen-driven growth [2]; together with human epidermal growth factor receptor 2 (HER2), these are the basis of the molecular subtyping of breast cancers [3]. This evidence concerns the gene ESR1 and neoplasm.